Ajinomoto CELLiST Korea Launches CELLiSTTM AAV Production Supplement 1 to Boost Gene Therapy Production Efficiency

This breakthrough supplement was developed through collaboration between Ajinomoto Co., Inc. (Tokyo, Japan) and its U.S.-based consolidated subsidiary, Forge Biologics, a leading CDMO specializing in adeno-associated virus (AAV)^*3 development and manufacturing. Demonstration studies confirmed that CELLiSTTM AAV Production Supplement 1 improves the productivity of viral vector manufacturing by 1.3 to 2 times^*4 compared to conventional culture methods. The results of this joint research were presented at the Japan Society of Gene and Cell Therapy (JSGCT) in July 2025.

The advancement addresses one of the most critical challenges in the fast-growing gene therapy field — improving productivity while reducing manufacturing costs. With the global gene therapy market projected to expand from USD 7 billion in 2022 to USD 46 billion by 2030^*5, efficient production solutions like CELLiSTTM AAV Production Supplement 1 are essential to meet rising demand for both prevalent and rare disease therapies.

For over three decades, Ajinomoto CELLiST Korea has been committed to innovation in the biopharmaceutical field, offering high-performance CELLiSTTM culture media optimized for CHO^*6 and HEK293 cell lines. By combining the Ajinomoto Group’s advanced formulation optimization technologies with Forge Biologics’ large-scale AAV manufacturing expertise, the launch of CELLiSTTM AAV Production Supplement 1 represents a significant step forward in applying AminoScience to accelerate the future of gene therapy manufacturing.　Ajinomoto CELLiST Korea will leverage CELLiSTTM AAV Production Supplement 1 to support customers mainly in Asia seeking to enhance their viral vector production efficiency.

“We are excited to introduce CELLiSTTM AAV Production Supplement 1 to our customers,” said President Sugiyama of Ajinomoto CELLiST Korea. “Building on the Ajinomoto Group’s strong R&D foundation, our goal is to help gene therapy developers achieve higher productivity, better scalability, and more reliable outcomes in their manufacturing processes.”

Ajinomoto CELLiST Korea remains committed to advancing the AminoScience-based solutions that drive innovation in biopharmaceutical manufacturing — from monoclonal antibodies to next-generation cell and gene therapies.

About Ajinomoto CELLiST Korea
Ajinomoto CELLiST Korea is a subsidiary of the Ajinomoto Group specializing in the production and sales of high-quality cell culture media for biopharmaceutical manufacturing. Through its CELLiST^TM brand, the company provides tailored media solutions including Basal media, Feeds, and CELLiST^TM AAV Production Supplement 1 to support customers’ productivity and quality goals.
For more information, please visit www.ajinomotocellistkorea.com

*1 A general term for carriers that mediate genetic information into the body; in gene therapy, it refers to vehicles that deliver therapeutic genes to cells. Those based on adeno-associated virus are called AAV vectors.
*2 A medical technology that treats genetic abnormalities causing diseases by repairing or adding genes within cells.
*3 Adeno-associated virus: Non-pathogenic and capable of delivering genomes to cells regardless of whether they are dividing or resting, making it useful for gene therapy. It efficiently delivers normal genes to cells with defective genes, enabling the synthesis of normal proteins.
*4 Results based on our company’s culture conditions.
*5 Ajinomoto IR materials.
*6 Abbreviation for Chinese Hamster Ovary Cell.